Literature DB >> 32603521

Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire.

Katrina Hueniken1, Catriona M Douglas2,3, Ashok R Jethwa2,3, Maryam Mirshams4, Lawson Eng4, Andrew Hope5, Douglas B Chepeha2,3, David P Goldstein2,3, Jolie Ringash5, Aaron Hansen4, Rosemary Martino6,7, Madeline Li8, Geoffrey Liu4,9,10, Wei Xu1, John R de Almeida2,3.   

Abstract

BACKGROUND: The treatment of head and neck cancer (HNC) may cause significant financial toxicity to patients. Herein, the authors have presented the development and validation of the Financial Index of Toxicity (FIT) instrument.
METHODS: Items were generated using literature review and were based on expert opinion. In item reduction, items with factor loadings of a magnitude <0.3 in exploratory factor analysis and inverse correlations (r < 0) in test-retest analysis were eliminated. Retained items constituted the FIT. Reliability tests included internal consistency (Cronbach α) and test-retest reliability (intraclass correlation). Validity was tested using the Spearman rho by comparing FIT scores with baseline income, posttreatment lost income, and the Financial Concerns subscale of the Social Difficulties Inventory. Responsiveness analysis compared change in income and change in FIT between 12 and 24 months.
RESULTS: A total of 14 items were generated and subsequently reduced to 9 items comprising 3 domains identified on exploratory factor analysis: financial stress, financial strain, and lost productivity. The FIT was administered to 430 patients with HNC at 12 to 24 months after treatment. Internal consistency was good (α = .77). Test-retest reliability was satisfactory (intraclass correlation, 0.70). Concurrent validation demonstrated mild to strong correlations between the FIT and Social Difficulties Inventory Money Matters subscale (Spearman rho, 0.26-0.61; P < .05). FIT scores were found to be inversely correlated with baseline household income (Spearman rho, -0.34; P < .001) and positively correlated with lost income (Spearman rho, 0.24; P < .001). Change in income was negatively correlated with change in FIT over time (Spearman rho, -0.25; P = .04).
CONCLUSIONS: The 9-item FIT demonstrated internal and test-retest reliability as well as concurrent and construct validity. Prospective testing in patients with HNC who were treated at other facilities is needed to further establish its responsiveness and generalizability.
© 2020 American Cancer Society.

Entities:  

Keywords:  financial toxicity; head and neck cancer; psychosocial oncology; quality of life; survivorship

Mesh:

Year:  2020        PMID: 32603521     DOI: 10.1002/cncr.33032

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Psychometric properties of self-reported financial toxicity measures in cancer survivors: a systematic review.

Authors:  Zheng Zhu; Weijie Xing; Huan Wen; Yanling Sun; Winnie K W So; Lucylynn Lizarondo; Jian Peng; Yan Hu
Journal:  BMJ Open       Date:  2022-06-24       Impact factor: 3.006

2.  Development and Validation of Subjective Financial Distress Questionnaire (SFDQ): A Patient Reported Outcome Measure for Assessment of Financial Toxicity Among Radiation Oncology Patients.

Authors:  Mukhtar Ahmad Dar; Richa Chauhan; Krishna Murti; Vinita Trivedi; Sameer Dhingra
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 6.244

3.  Out-of-pocket costs associated with head and neck cancer treatment.

Authors:  Mohemmed N Khan; Katrina Hueniken; Mirko Manojlovic-Kolarski; Lawson Eng; Maryam Mirshams; Khaleeq Khan; Colleen Simpson; Michael Au; Geoffrey Liu; Wei Xu; Christopher J Longo; David P Goldstein; Jolie Ringash; Rosemary Martino; Aaron R Hansen; John R de Almeida
Journal:  Cancer Rep (Hoboken)       Date:  2021-08-24

4.  Financial toxicity in female patients with breast cancer: a national cross-sectional study in China.

Authors:  Meicen Liu; Linlin Hu; Xueyan Han; Man Cao; Jing Sun; Yuanli Liu
Journal:  Support Care Cancer       Date:  2022-07-11       Impact factor: 3.359

Review 5.  Evidence of the Feasibility and Preliminary Efficacy of Oncology Financial Navigation: A Scoping Review.

Authors:  Meredith J Doherty; Bridgette Thom; Francesca Gany
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-08-02       Impact factor: 4.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.